These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 10890575)

  • 1. Selective estrogen receptor modulators in reproductive medicine and biology.
    Baker VL; Leitman D; Jaffe RB
    Obstet Gynecol Surv; 2000 Jul; 55(7 Suppl 2):S21-47. PubMed ID: 10890575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of breast cancer: implications for postmenopausal women.
    Fabian CJ; Kimler BF
    Drugs Aging; 2002; 19(1):43-78. PubMed ID: 11929326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Specific estrogen receptor modulators (SERMs)].
    Trémollières F; Lopes P
    Presse Med; 2002 Sep; 31(28):1323-8. PubMed ID: 12355995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review.
    Ang WC; Farrell E; Vollenhoven B
    Climacteric; 2001 Dec; 4(4):284-92. PubMed ID: 11770184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel agents to modulate oestrogen action.
    Dardes RC; Jordan VC
    Br Med Bull; 2000; 56(3):773-86. PubMed ID: 11255561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective estrogen receptor modulators and phytoestrogens: new therapies for the postmenopausal women.
    Fitzpatrick LA
    Mayo Clin Proc; 1999 Jun; 74(6):601-7. PubMed ID: 10377937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
    Draper MW
    Ann N Y Acad Sci; 2003 Nov; 997():373-7. PubMed ID: 14644844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor modulators: a look ahead.
    Mitlak BH; Cohen FJ
    Drugs; 1999 May; 57(5):653-63. PubMed ID: 10353293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
    Chmel R; Rob L; Strnad P
    Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raloxifene: a new choice for treating and preventing osteoporosis.
    Licata AA; Ciaccia AV; Wong M; Draper MW
    Cleve Clin J Med; 2000 Apr; 67(4):273-80. PubMed ID: 10780099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene: A selective estrogen receptor modulator (SERM) with multiple target system effects.
    Muchmore DB
    Oncologist; 2000; 5(5):388-92. PubMed ID: 11040275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors.
    Walsh BW
    Ann N Y Acad Sci; 2001 Dec; 949():163-7. PubMed ID: 11795349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of raloxifene and its clinical application.
    Hochner-Celnikier D
    Eur J Obstet Gynecol Reprod Biol; 1999 Jul; 85(1):23-9. PubMed ID: 10428318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1.
    Dahm AE; Iversen N; Birkenes B; Ree AH; Sandset PM
    BMC Cardiovasc Disord; 2006 Oct; 6():40. PubMed ID: 17029634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen modulators in menopause.
    Gambacciani M
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women.
    Vogelvang TE; van der Mooren MJ; Mijatovic V; Kenemans P
    Drugs; 2006; 66(2):191-221. PubMed ID: 16451093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.